-
- Katarina Riesner
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Yu Shi
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Angela Jacobi
- Biotechnology Center, and
-
- Martin Kräter
- University Clinic Carl Gustav Carus Dresden, Medical Clinic and Polyclinic 1, Technical University Dresden, Dresden, Germany; and
-
- Martina Kalupa
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Aleixandria McGearey
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Sarah Mertlitz
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Steffen Cordes
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Jens-Florian Schrezenmeier
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Jörg Mengwasser
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Sabine Westphal
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Daniel Perez-Hernandez
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
-
- Clemens Schmitt
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
-
- Gunnar Dittmar
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
-
- Jochen Guck
- Biotechnology Center, and
-
- Olaf Penack
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin, Germany;
説明
<jats:title>Key Points</jats:title><jats:p>Angiogenesis preceded infiltration of inflammatory leukocytes during GVHD as well as during experimental colitis. Metabolic alterations and cytoskeleton changes occurred during early angiogenesis, but classical endothelial activation signs were absent.</jats:p>
収録刊行物
-
- Blood
-
Blood 129 (14), 2021-2032, 2017-04-06
American Society of Hematology